Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2008 2
2009 1
2013 1
2016 1
2017 1
2018 4
2019 7
2020 7
2021 7
2022 13
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Effect of treatment periods on efficacy of glecaprevir and pibrentasvir in chronic hepatitis C: A nationwide, prospective, multicenter study.
Morita A, Tamaki N, Kobashi H, Mori N, Tsuji K, Takaki S, Hasebe C, Akahane T, Ochi H, Mashiba T, Urawa N, Fujii H, Mitsuda A, Kondo M, Ogawa C, Uchida Y, Narita R, Marusawa H, Kubotsu Y, Matsushita T, Shigeno M, Yoshida H, Tanaka K, Okamoto E, Kasai T, Ishii T, Okada K, Kurosaki M, Izumi N. Morita A, et al. Among authors: akahane t. JGH Open. 2024 Apr 25;8(4):e13068. doi: 10.1002/jgh3.13068. eCollection 2024 Apr. JGH Open. 2024. PMID: 38681824 Free PMC article.
Usefulness of the Fibrosis-4 index and alanine aminotransferase at 1 year of nucleos(t)ide analog treatment for prediction of hepatocellular carcinoma in chronic hepatitis B patients.
Inoue J, Akahane T, Kobayashi T, Kimura O, Sato K, Ninomiya M, Iwata T, Takai S, Kisara N, Sato T, Nagasaki F, Miura M, Nakamura T, Umetsu T, Sano A, Tsuruoka M, Onuki M, Sawahashi S, Niitsuma H, Masamune A; THERME Study Group. Inoue J, et al. Among authors: akahane t. Hepatol Res. 2024 Feb;54(2):131-141. doi: 10.1111/hepr.13957. Epub 2023 Sep 6. Hepatol Res. 2024. PMID: 37621201
Necessity for surveillance for hepatocellualr carcinoma in older patients with chronic hepatitis C who achieved sustained virological response.
Ishido S, Tamaki N, Kurosaki M, Mori N, Tsuji K, Hasebe C, Mashiba T, Ochi H, Yasui Y, Akahane T, Furuta K, Kobashi H, Fujii H, Ishii T, Marusawa H, Kondo M, Kusakabe A, Yoshida H, Uchida Y, Tada T, Nakamura S, Mitsuda A, Ogawa C, Arai H, Murohisa T, Uebayashi M, Izumi N. Ishido S, et al. Among authors: akahane t. JGH Open. 2023 May 29;7(6):424-430. doi: 10.1002/jgh3.12914. eCollection 2023 Jun. JGH Open. 2023. PMID: 37359109 Free PMC article.
Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group.
Takaki S, Kurosaki M, Mori N, Tsuji K, Ochi H, Marusawa H, Nakamura S, Tada T, Narita R, Uchida Y, Akahane T, Kondo M, Kusakabe A, Furuta K, Kobashi H, Arai H, Nonogi M, Tamada T, Hasebe C, Ogawa C, Sato T, Tamaki N, Yasui Y, Tsuchiya K, Izumi N. Takaki S, et al. Among authors: akahane t. Invest New Drugs. 2023 Apr;41(2):340-349. doi: 10.1007/s10637-023-01349-4. Epub 2023 Mar 30. Invest New Drugs. 2023. PMID: 36995548
Switching to Tenofovir Alafenamide Fumarate in Chronic Hepatitis B Patients Who Had Detectable HBV DNA during Treatment with Entecavir.
Sato K, Inoue J, Akahane T, Kobayashi T, Takai S, Nakamura T, Sato T, Kimura O, Ninomiya M, Iwata T, Sano A, Tsuruoka M, Onuki M, Sawahashi S, Niitsuma H, Masamune A. Sato K, et al. Among authors: akahane t. Tohoku J Exp Med. 2022 Nov 12;258(4):277-285. doi: 10.1620/tjem.2022.J084. Epub 2022 Oct 14. Tohoku J Exp Med. 2022. PMID: 36244758 Free article.
Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B.
Kaneko S, Kurosaki M, Mashiba T, Marusawa H, Kondo M, Kojima Y, Uchida Y, Fujii H, Akahane T, Yagisawa H, Kusakabe A, Kobashi H, Abe T, Yoshida H, Ogawa C, Furuta K, Tamaki N, Tsuji K, Matsushita T, Izumi N; Japanese Red Cross Liver Study Group. Kaneko S, et al. Among authors: akahane t. J Med Virol. 2023 Jan;95(1):e28210. doi: 10.1002/jmv.28210. Epub 2022 Oct 20. J Med Virol. 2023. PMID: 36222204
Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study.
Sato K, Inoue J, Akahane T, Kobayashi T, Sato S, Kisara N, Ninomiya M, Iwata T, Sano A, Tsuruoka M, Onuki M, Masamune A. Sato K, et al. Among authors: akahane t. Medicine (Baltimore). 2022 Sep 30;101(39):e30630. doi: 10.1097/MD.0000000000030630. Medicine (Baltimore). 2022. PMID: 36181074 Free PMC article. Clinical Trial.
Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.
Tamaki N, Tada T, Kurosaki M, Yasui Y, Ochi H, Mashiba T, Sakamoto A, Marusawa H, Narita R, Uchida Y, Akahane T, Kondo M, Mori N, Takaki S, Tsuji K, Kobashi H, Kusakabe A, Furuta K, Arai H, Nonogi M, Ogawa C, Sato T, Tamada T, Nakamura S, Hasebe C, Tsuchiya K, Izumi N. Tamaki N, et al. Among authors: akahane t. Invest New Drugs. 2022 Dec;40(6):1290-1297. doi: 10.1007/s10637-022-01303-w. Epub 2022 Sep 24. Invest New Drugs. 2022. PMID: 36152108
Usefulness of neutrophil-to-lymphocyte ratio in predicting progression and survival outcomes after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
Ochi H, Kurosaki M, Joko K, Mashiba T, Tamaki N, Tsuchiya K, Marusawa H, Tada T, Nakamura S, Narita R, Uchida Y, Akahane T, Kondo M, Mori N, Takaki S, Tsuji K, Kusakabe A, Furuta K, Kobashi H, Arai H, Nonogi M, Tamada T, Hasebe C, Izumi N. Ochi H, et al. Among authors: akahane t. Hepatol Res. 2023 Jan;53(1):61-71. doi: 10.1111/hepr.13836. Epub 2022 Oct 4. Hepatol Res. 2023. PMID: 36070216
General evaluation score for predicting the development of hepatocellular carcinoma in patients with advanced liver fibrosis associated with hepatitis C virus genotype 1 or 2 after direct-acting antiviral therapy.
Tada T, Kurosaki M, Tamaki N, Yasui Y, Mori N, Tsuji K, Hasebe C, Joko K, Akahane T, Furuta K, Kobashi H, Fujii H, Ishii T, Marusawa H, Kondo M, Kojima Y, Yoshida H, Uchida Y, Nakamura S, Izumi N. Tada T, et al. Among authors: akahane t. JGH Open. 2022 Jun 8;6(7):487-495. doi: 10.1002/jgh3.12778. eCollection 2022 Jul. JGH Open. 2022. PMID: 35822118 Free PMC article.
43 results